Shares of Lords Mark Industries continued gaining momentum on Monday, September 21, as well, hitting a back-to-back upper circuit amid sustained buying momentum and positive sentiment in the stock market. The company’s stock, which has a diversified presence across healthcare, including diagnostics, MedTech, dialysis, and advanced medical technologies, started the session in the green at Rs 89.58 from the last close of Rs 89 on the BSE. The scrip built momentum further to touch the intraday high at Rs 93.45, hitting the 5 per cent upper circuit.
Meanwhile, the company's market cap stood at over Rs 3,900 crore. The stock’s 52-week high was Rs 669.70 and a 52-week low was Rs 60.00.
The rally in the diversified healthcare stock came amid the company targeting revenue of around Rs 825 crore for the current fiscal year (FY27) on the back of growth in its IVD, MedTech, and dialysis businesses.
Share Price History
The stock has been gaining momentum for the past four sessions, advancing over 15 per cent. According to BSE Analytics, Lords Mark Industries shares have corrected over 66 per cent in a five-year period. However, the stock rose over 11.14 per cent in one month compared to a 3.47 per cent fall in the benchmark index. In the last 5 days, the stock jumped over 13 per cent; in the last six months, it rose over 47 per cent.
Also Read: Sensex Up 493 Points: Ease In Crude Prices, FPI Inflow And Positive Global Cues Fuel Sentiment
Revenue Expectations and Phase 1 Expansion Plan
During its September investor presentation, management projected revenues of approximately Rs 825 crore for FY27 across the IVD, MedTech, and dialysis divisions. These projections reflect forward-looking guidance rather than confirmed earnings. For comparison, the group posted a consolidated revenue of Rs 307.68 crore with a net profit (PAT) of Rs 33.18 crore for the quarter ending June 2026.
Additionally, the firm aims to expand its dialysis network using AI-integrated technology. As of September, it reported securing orders exceeding 500 dialysis units and set a goal to open 50 functional dialysis facilities by March 2027.
Completion of Phase I expansion
The company previously announced that Phase 1 of the expansion at its Silvassa unit was completed roughly three months ahead of the original December 2026 deadline.
Also Read: NSE IPO Day 2 Subscription Status Reaches 100%: Does GMP Signal A Subdued Listing?
Disclaimer: This story is for informational purposes only. It should not be construed as investment advice. Please seek expert advice before investing.